StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Total Biopharma Alliance Revenues by Year

Total Biopharma Alliance Revenues (cross-portfolio summary) — Worldwide revenues ($M) ($M)

Pfizer Total Biopharma Alliance Revenues: $9,266M in FY2025, up 10.5% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
9,266
Period ended Dec 31, 2025
Change on a year earlier
+10.5%
8,388 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Total Alliance revenues included above | $ | 9,266 | $ | 8,388 | 10% | 10% | $ | 7,209 | $ | 6,575 | 10% | $ | 2,057 | $ | 1,813 | 13% | 11%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up total Biopharma Alliance Revenues

Cite this data

StockData. (2026). Pfizer Total Biopharma Alliance Revenues ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/alliance-rev-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.